Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: PG stock price vs BRKR: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at BRKR's multiple
Needs Annual EPS, BRKR P/E.
Implied fair value · at PG's multiple
Needs Annual EPS, PG P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Higher is better
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
PROCTER & GAMBLE Co · implied price per share
Reporting currency could not be verified.
BRUKER CORP · implied price per share
Reporting currency could not be verified.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
PG · not enough data.
BRKR · not enough data.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
COLGATE PALMOLIVE CO
PG vs CL
KIMBERLY CLARK CORP
PG vs KMB
CHURCH & DWIGHT CO INC /DE/
PG vs CHD
CLOROX CO /DE/
PG vs CLX
Johnson & Johnson
PG vs JNJ
THERMO FISHER SCIENTIFIC INC.
PG vs TMO
DANAHER CORP /DE/
PG vs DHR
AGILENT TECHNOLOGIES, INC.
PG vs A
WATERS CORP /DE/
PG vs WAT
BIO-RAD LABORATORIES, INC.
PG vs BIO
BIO-TECHNE Corp
PG vs TECH
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe PG can sustain its current premium multiple despite only 0.3% revenue growth and a P/S-implied downside of 30.7%, then hold or avoid adding; if you want a relative-value setup, the data favors waiting for a lower entry price because PG already screens above BRKR-derived fair value estimate.
The valuation gap is unfavorable for PG: the current price of $144.49 is 30.7% above the P/S-implied price of $100.16. PG also sits above the top of its historical band at $158.94 only partially, but the model’s implied range and BRKR comparison both point to downside rather than upside.
Supporting Metrics
